Nuwellis, Inc.
Close on Oct 19, 2026
- Market cap
- $101.13K
- P/E (TTM)
- –
- Dividend yield
- –
About Nuwellis
Electromedical & Electrotherapeutic Apparatus, SIC 3845
Nuwellis, Inc. is a medical technology company dedicated to advancing cardiorenal care through specialized fluid management solutions. The company develops, manufactures, and commercializes medical devices designed for ultrafiltration therapy, primarily the Aquadex SmartFlow and Aquadex FlexFlow systems. These devices remove excess fluid and salt from patients experiencing hypervolemia or fluid overload who have proven unresponsive to conventional medical treatments, such as diuretics. Nuwellis focuses its commercial offerings on three primary clinical sectors: pediatrics, critical care, and heart failure.
The company distributes its products to healthcare providers and hospital systems, with commercial activities focused in the United States across inpatient and critical care settings. Nuwellis maintains its principal executive offices and corporate headquarters in Eden Prairie, Minnesota.
Summary of the business section of Nuwellis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nuwellis, Inc.
- Headquarters
- Eden Prairie, MN
- Address
- 12988 Valley View Road 55344
- Phone
- (952) 345-4200
- Employees
- 24, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- NUWE
- Exchange
- Nasdaq
- IPO date
- Aug 10, 2012
- Shares outstanding
- 4M, Aug 10, 2026
- Public float
- $4.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-35 reverse, Aug 13, 2026; 1-for-35 reverse, Jun 26, 2026; 1-for-42 reverse, Jul 7, 2025; 1-for-42 reverse, Jun 19, 2025; 1-for-35 reverse, Jun 28, 2024; 1-for-35 reverse, Jun 27, 2024; 1-for-100 reverse, Dec 12, 2022; 1-for-99 reverse, Dec 8, 2022; 1-for-30 reverse, Oct 19, 2020; 1-for-30 reverse, Oct 9, 2020; 1-for-14 reverse, Jan 31, 2019; 1-for-14 reverse, Jan 3, 2019; 1-for-20 reverse, Oct 13, 2017; 1-for-20 reverse, Oct 12, 2017; 1-for-30 reverse, Jan 13, 2017; 1-for-30 reverse, Jan 12, 2017
- SEC CIK
- 1506492
- CUSIP
- 67113Y801
- ISIN
- US67113Y8012
- LEI
- 54930007LBO6YS5KNX75
- EIN
- 68-0533453
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Kendrick McCormick | President and CEO, Director | – |
| John L. Erb | CEO and President, Director | 1,100,022 |
| Carisa Schultz | Chief Financial Officer | – |
| Martin J. Emerson | Director | – |
| Gregory D. Waller | Director | 2 |
| David McDonald | Director | – |
| Archelle Georgiou Feldshon | Director | – |
| Katharyn Field | Director | – |
| Mika Grasso | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr Erb | $336.18K | $313.32K | $306.10K | $0 | – |
| FY2025 Mr Jaramillo | $324.33K | $324.33K | $306.10K | $0 | – |
| FY2024 Mr Erb | $0 | $0 | $288.47K | $0 | – |
| FY2024 Mr Jaramillo | $409.41K | $387.86K | $288.47K | $0 | – |
| FY2023 | $606.60K | $423.66K | $446.46K | $0 | – |
| FY2023 Mr Erb | $0 | $0 | $446.46K | $0 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 24 full-time employees in sales and marketing.”
Corporate history
Events identified from SEC filings